The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

Learn spawn camping strategies in Battlefield 6. This tutorial teaches new players about the dangers and tactics of spawn camping in #BF6. WSJ opinion: The Democrats’ instant no Nancy Guthrie ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...

Add Yahoo as a preferred source to see more of our stories on Google. Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly.

Oct 31 (Reuters) - Dexcom (DXCM.O), opens new tab shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street ...

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as the continuous glucose monitoring (CGM) equipment maker managed to retain ...

It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Dexcom Netherlands, a healthcare band, successfully raised awareness about living with diabetes through its 24/7 Diabetes campaign, reaching millions and significantly increasing brand recognition.

Dexcom has recalled its G6, G7, ONE, and ONE+ continuous glucose monitor (CGM)receivers due to a speaker malfunction that could cause missed low or high blood sugar alerts. The recall, for which ...

We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at where DexCom Inc. (NASDAQ:DXCM) stands against other firms that soared last ...

DexCom Inc (NASDAQ:DXCM) reported accelerating revenue growth in its first quarter of 2025, though the continuous glucose monitoring (CGM) leader faces margin pressures as it expands its product ...